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Abstract
Background: Recently, metagenomic studies have identified viable Pepper mild mottle virus (PMMoV), a plant virus, in the
stool of healthy subjects. However, its source and role as pathogen have not been determined.
Methods and Findings: 21 commercialized food products containing peppers, 357 stool samples from 304 adults and 208
stool samples from 137 children were tested for PMMoV using real-time PCR, sequencing, and electron microscopy. Anti-
PMMoV IgM antibody testing was concurrently performed. A case-control study tested the association of biological and
clinical symptoms with the presence of PMMoV in the stool. Twelve (57%) food products were positive for PMMoV RNA
sequencing. Stool samples from twenty-two (7.2%) adults and one child (0.7%) were positive for PMMoV by real-time PCR.
Positive cases were significantly more likely to have been sampled in Dermatology Units (p,10
26), to be seropositive for
anti-PMMoV IgM antibodies (p=0.026) and to be patients who exhibited fever, abdominal pains, and pruritus (p=0.045,
0.038 and 0.046, respectively).
Conclusions: Our study identified a local source of PMMoV and linked the presence of PMMoV RNA in stool with a specific
immune response and clinical symptoms. Although clinical symptoms may be imputable to another cofactor, including
spicy food, our data suggest the possibility of a direct or indirect pathogenic role of plant viruses in humans.
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Introduction
Little is known regarding the viral flora present in the human
gastrointestinal tract [1–5]. Recently, viral communities have
been examined in non-diarrheic human stool in a systematic and
unbiased fashion using metagenomics [6–7]. Interestingly, the
vast majority of the recovered viral sequences corresponded to
uncultured pathogenic plant RNA viruses [7]. The most
abundant viral sequences isolated were from the Pepper mild mottle
virus (PMMoV), with up to 10
9 virions per gram of dry weight
fecal matter. PMMoV is a non-enveloped, rod-shaped, single-
stranded positive sense RNA virus classified in the genus
Tobamovirus, which includes viruses extremely resistant to physical
and chemical agents [8–9]. It is one of the major pathogens of
Capsicum spp (chili peppers). Complementary data from Zhang
et al.’s study have shown that PMMoV could be detected in non-
diarrheic stool from 12 out of 18 individuals living in San Diego,
USA or in Singapore, suggesting it might be geographically
widespread, and in 3 out of 22 fresh and processed pepper
samples. Moreover, the fecal PMMoV was viable and could
infect host plants.
In the present study, we determined if PMMoV could be
detected in commercial food products in our geographical area or
the stool of patients and if these viruses were associated with
biological and clinical symptoms.
Materials and Methods
Food products and human stool collection
Twenty-eight commercial food products were purchased in
various grocery stores and supermarkets in Marseille (France) and
stored at room temperature until processing (Table 1). They
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containing peppers, four products containing spice and seven
products not known to contain pepper. For solid food products,
1 ml of the product was diluted in 1 ml of 16PBS. Additionally,
565 stool samples were obtained between March and September
2008 for microbial diagnosis independent of the present study and
approximately 1 ml collected randomly from each stool was stored
in 1 ml of 16 PBS at +4uC. Of these samples, 357 were from
adults (.18 years of age) and 208 were from children (,18 years
of age). This study has been approved by our institutional ethics
committee (Comite ´ d’Ethique de l’IFR48, Universite ´d el a
Me ´diterrane ´e; review no. 09-001), that waived the need for
consent.
PMMoV RNA extraction
Viral RNA was extracted from 200 mlo ft h ef e c a l
supernatant or the solid food product suspensions following
centrifugation at 10,000 g for 10 min or directly from the
liquid food products by using the MagNA Pure LC RNA
Isolation Kit (Roche Diagnostics, Meylan, France). The
prepared RNA was directly analyzed or stored at 280uCu n t i l
processing.
Detection of PMMoV RNA by real-time PCR
PMMoV RNA was detected using a real-time reverse
transcription (RT)-PCR assay with SuperScript III Platinum
One-Step Quantitative RT-PCR System (Invitrogen Life Tech-
nologies, Carlsbad, Calif., USA) on an Mx3000P thermocycler
(Stratagene, La Jolla, CA 92037 USA). Each 25 ml reaction
contained 10 ml of the extracted viral RNA, 12.5 ml2 6reaction
mix, 0.5 ml of SuperScript III/RT Platinum Taq mix, and 0.75 ml
(10 pmol/ml) of each primer and 0.5 ml (10 pmol/ml) of probe
described by Zhang et al [7]. Positive samples were further tested
by RT-PCR amplification and sequencing, as well as electron
microscopy.
Infection of host plants with PMMoV RNA-positive food
products
The viability and infectivity of PMMoV recovered from two
PMMoV RNA-positive powder or dried food-products (no. 8, 17)
and from a PMMoV RNA-positive Tabasco sample were tested by
mechanical inoculation to host plants. Powder or dried food-
products were crushed then mixed with an inoculation solution
containing Na2HPO4 0.03M and 0.2% (wt/vol) Na-diethyldithio-
Table 1. PMMoV RNA sequences recovered from food products.
no.
Presence of Capsicum spp or spice
notified in food product composition Type of food product Food product Origin
PMMoV RNA
sequencing
1 No Fruit or vegetable Tomato Unknown Neg
2 No Sauce Salad sauce Unknown Neg
3 No Sauce Mayonnaise France Neg
4 No Sauce Oil France Neg
5 No Sauce ‘‘Exotic’’ sauce France Neg
6 No Sauce Tomato sauce Unknown Neg
7 No Sauce Vinegar Unknown Neg
8 Spice Powder or dried food-product Spicy powder no.1 Unknown Pos
9 Spice Powder or dried food-product Spicy powder no.2 Mexico Pos
10 Spice Sauce BBK sauce Unknown Pos
11 Spice Sauce Ketchup sauce Europe Neg
12 Yes Fruit or vegetable Green chili pepper Morrocco Neg
13 Yes Fruit or vegetable Red chili pepper no.1 Morrocco Neg
14 Yes Fruit or vegetable Red chili pepper no.2 Unknown Pos
15 Yes Fruit or vegetable Yellow chili pepper Unknown Neg
16 Yes Powder or dried food-product Cayenne pepper no.1 France Pos
17 Yes Powder or dried food-product Cayenne pepper no.2 Unknown Pos
18 Yes Powder or dried food-product Chili pepper and cumin powder Mexico Neg
19 Yes Powder or dried food-product Cumin powder Unknown Neg
20 Yes Powder or dried food-product Curry powder Unknown Pos
21 Yes Powder or dried food-product Red chili pepper powder Unknown Pos
22 Yes Sauce Chili pepper based-vinegar Unknown Neg
23 Yes Sauce Combava and chili pepper-based
sauce
Unknown Neg
24 Yes Sauce Harissa sauce Unknown Neg
25 Yes Sauce Tabasco sauce no.1 USA Pos
26 Yes Sauce Tabasco sauce no.2 USA Pos
27 Yes Sauce Tabasco sauce no.3 USA Pos
28 Yes Sauce Tabasco sauce no.4 USA Pos
doi:10.1371/journal.pone.0010041.t001
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0.5 M phosphate buffer (Na2HPO4-KH2PO4, pH 7.2), then
filtered, and 8% (vol/vol) of n-butanol was added. After agitation
for 15 min, centrifugation was performed at 10,000 g for 30 min
at 10uC, and the supernatant was collected and filtered. Then, 4%
(wt/vol) Polyethyleneglycol 6000 and 4% (wt/vol) NaCl were
added prior to stirring for 15 min then centrifugation at 10,000 g
and 10uC for 15 min. Pellets were resuspended in 1 ml of 0.01 M
phosphate buffer. Samples were mixed with 600 mesh Carborun-
dum and 200 ml were inoculated mechanically to three leaves of
two plants of Nicotiana tabacum var Xanthi NN, a hypersensitive
host for PMMoV. Negative controls were the same numbers of
plants either not inoculated or inoculated with the buffer only. All
plants were kept for two weeks in the same unit of an insect-proof
greenhouse. Local lesions typical of PMMoV infection were
excised and crushed into 0.6 ml of inoculation buffer, and 350 ml
of this solution were tested for the presence of PMMoV by RT-
PCR using primers published by Hamada et al. [10], by electron
microscopy, and by inoculation to one plant of Capsicum annuum
var Yolo Wonder or Nicotiana benthamiana, two susceptible hosts for
PMMoV.
PMMoV RNA sequencing and phylogenetic analysis
PMMoV sequences corresponding to two different regions of
the PMMoV genome were obtained by RT-PCR amplification
using the SuperScript One-Step RT-PCR System (Invitrogen Life
Technologies) and primers that had been designed with the
SVARAP program [11]. The first targeted region is located near
the 59 end of the genome (primers used are PMMoV5pFwd: 59-
ATATCTGATGATGCAAGTTC-39, 348 (the primer location
was defined in reference to sequence GenBank accession nb
NC_003630); PMMoV5p_Rev2: 59-TAAACCTCTCTATTA-
GAGGC-39, 928), and the second region corresponds to a
fragment of the capsid gene (primers are PMMoVcaps_Fwd: 59-
CGTTAGGyAATCAGTTTCAA-39, 5776; PMMoVcaps_Rev2:
59-CGAACTAACTCATTCATGA-39, 6070). For RT-PCR am-
plification, five ml of extracted viral RNA were added to 20 ml
reaction solution containing 0.5 ml (10 pmol/ml) of primers,
12.5 mlo f2 6 reaction buffer, and 0.5 ml of RT/Platinum Taq
mix. RT-PCR reaction was conducted under the following
conditions: 45uC for 30 min for RT, 94uC for 2 min for initial
denaturation, followed by 40 cycles of denaturation at 94uC for
30 s, annealing at 56uC for 45 s, elongation at 72uC for 2 min,
then final elongation step at 72uC for 5 min. PCR products were
purified with Sephadex G-50 Superfine on MAHVN 4550 plates
(Millipore, Molsheim, France) then sequenced by using the
amplification PCR primers and the Big Dye Terminator cycle
sequencing kit version 1.1 on the ABI Prism 3130 genetic analyzer
(Applied Biosystems, Branchburg, NJ, USA). The phylogenetic
analysis was performed using Mega v.4.1 software (http://www.
megasoftware.net/).
PMMoV purification from Tabasco sauce
Tabasco sauce (50 ml) was centrifuged at low speed (2,000 rpm)
for 20 min. The PMMoV-containing supernatant (30 ml) was
then treated with 1 M NaCl (30 ml) at 4uC overnight and filtered
using a 5 mm Millex-SV filter (Millipore). The filtrate was loaded
onto a caesium chloride (CsCl) density gradient consisting of 1 ml
layers of 1.7, 1.5 and 1.30 g/ml CsCl in 16 PBS. After
ultracentrifugation (22,000 g for 2 h at 4uC), the 1.30–1.50 g/ml
fraction containing the purified PMMoV (r=1.31) was collected.
This fraction was washed on a Microcon 100 centrifugal filter
(Millipore) with 16PBS.
Electron microscopy study of PMMoV
A4 0 ml aliquot of Tabasco sauce or fecal supernatant was
deposited on a nickel 400 mesh Formvar carbon grid (EMS, Fort
Washington, PA). After 15 min at 37uC, staining was performed
with 1% ammonium molybdate for 10 sec. The stained grids were
examined with a transmission electron microscope (Philips
Morgagni 268D at 80Kv) after they were dried for 30 min at
room temperature. The sensitivity of detection is estimated to be
10
6–10
8 virus particles/ml [12]. In addition, immunogold staining
was performed, prior to electron microscopy, on PMMoV purified
from PMMoV RNA-positive Tabasco sauce and stool, as follows:
the electron microscopic grids were fixed with PBS and 1%
glutaraldehyde for 2 min. After rinsing with PBS for 2 min, the
grids were incubated twice for 5 min with 50 mM NH4Cl in PBS,
preincubated twice for 2 min with Solution 1 (1% bovine serum
albumine (BSA), 1% normal goat serum, 0.2% tween 20 in PBS)
and incubated for 90 min with a polyclonal anti-PMMoV mouse
antibody at 1:1 dilution in Solution 1. These antibodies had been
produced in two 6-week-old female Balb/C mice inoculated
intraperitoneally with 1.3 mg of purified PMMoV using 400 mg
aluminum hydroxide and 10 mg non-methylated oligonucleotides
containing CpG motifs as an adjuvant, as previously described
[13]. Blood collection was performed at day 38 following two
booster doses administered at day 14 and day 28. After rinsing the
stained grids with 0.1% BSA in PBS for 2 min, the grids were
preincubated in Solution 2 (0.01% fish gelatin in PBS), transferred
to a drop of gold-conjugated goat anti-mouse antibodies (diluted
1:40 in Solution 2) for 60 min, washed six times with Solution 2
and twice with PBS for 10 min each. The grids were fixed in 2%
glutaraldehyde for 15 min, then washed with PBS four times for
10 min and stained with 1% ammonium molybdate for 10 sec.
Two negative controls were concurrently tested using antibodies
derived from a non-immunized mouse or rotavirus instead of
PMMoV.
Anti-PMMoV ELISA
ELISA Nunc Maxisorp plates were coated with 100 ml PMMoV
solution per well (0.6 mg/ml purified from a PMMoV RNA-
positive Tabasco sauce) overnight at 4uC. All wells were machine-
washed thrice with 300ml 0.1% Tween in PBS and blocked with
200 ml of PBS containing 5% dried skimmed milk for 30 min at
room temperature with gentle agitation. The wells were washed
with 0.1% Tween in PBS, and 100 ml of serum diluted in 3% milk /
0.1% Tween in PBS was added. The plates were incubated for 1 h
at room temperature and washed as described above. After
washing, 100 ml of horseradish peroxidase–conjugated goat anti-
humantotalIgorIgM(BeckmanCoulter,Marseille,France)diluted
1:5000in3%milk/0.1%TweeninPBSwasadded.Theplateswere
then incubated for 1 hr at room temperature and washed as
described above. The plates were developed by adding 200 mlo f
ortho-phenylenediamine per well and the absorbance was read at
492 nm.
Analysis of risk factors and biological and clinical signs
associated with the presence of PMMoV RNA in stool or
anti-PMMoV antibodies in serum
A case-control study was performed to assess the potential risk
factors and the biological and clinical signs associated with the
presence of PMMoV in the stool. Eighteen case-patients were
compared to thirty-one control-patients with PMMoV RNA–
negative stool. When possible, two control-patients from the same
clinical units as the cases were selected for each case. The case-
and control-patients were matched by age and sex. The variables
PMMoV in Food/Patients’ Stool
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es and clinical and biological signs. A Microsoft Excel spread sheet
was used to enter the data. To identify risk factors for PMMoV
detection, univariate analysis was performed with the Epi Info
software version 3.3.2 (CDC, Atlanta, GA, USA). Proportions
were compared by using the Yates Chi-square corrected test or the
Fisher’s exact test while continuous variables were compared by
using either the ANOVA test or the Mann-Whitney/Wilcoxon
two-sample test when the data were not normally distributed. For
multivariate analysis, only variables with a p value #0.1 in
univariate analysis were kept in the final model. Binary logistic
regression analysis was performed using the SPSS software version
10 (Chicago, IL, USA).
Results
Detection of PMMoV RNA by real-time PCR
Food products. PMMoV RNA sequences were recovered
from twelve (57%) of the twenty-one pepper- or spice-containing
food products (Table 1). Tabasco sauce contained the highest viral
load, estimated to be nearly 10
7 PMMoV RNA copies/ml based on
a cycle threshold of 22 by real-time PCR or the presence of more
than one viral particle/field by electron microscopy (Figure 1a).
Stool from children. PMMoV RNA was detected in the
stool from only 1 child out of 137 (0.7%) using real-time PCR
(Table 2). The presence of PMMoV RNA was confirmed by
sequencing and viral particles compatible with PMMoV were
observed using electron microscopy. The patient was a 5-year-old
boy living in Marseille who was admitted to our institution because
of abdominal pains, fever, asthenia and hyperventilation.
Stool from adults. The stool from 22 of 304 (7.2%) adults
was positive for PMMoV by real-time PCR (Table 2). This
proportion was significantly higher than the incidence in children
(p=0.0043). PMMoV RNA sequence could be recovered from all
but two patients, whereas PMMoV-like viral particles were
observed, by electron microscopy, in the stool from all but one
patient, who was found positive for PMMoV RNA sequencing
(Figure 1d) . The proportion of PMMoV RNA–positive patients
was significantly higher in Dermatology Units than in other
clinical units (7/20 (35.0%) versus 15/284 (5.3%); p=7 610
27)
(Table 2). Clinical and biological data were obtained from 18 of
the 22 PMMoV-positive patients and compared to the
characteristics of 31 patients with PMMoV-negative stool. By
univariate analysis, abdominal pains, diverticulosis or diverticulitis,
and fever were significantly associated with PMMoV RNA-
positive stool (Table 3). No biological sign was significantly
associated with the presence of PMMoV RNA. By multivariate
analysis, using a model including age, gender and the variables
significantly associated with the case-patients in the univariate
analysis, fever (p=0.0447 (relative risk (RR), 5.290 (95%
confidence limits for RR (CI95), 1.040–26.911)), abdominal
pains (p=0.0376 (7.069 (1.119–44.660)), and pruritus (p=0.0460
(6.131 (1.033–36.402)) were independently associated with the
presence of PMMoV RNA. In addition, an interaction was
observed between abdominal pains and diverticulitis. Overall, the
model fitted the data well (Hosmer-Lemeshow test equal to 0.94).
Three of four patients with concurrent abdominal pains and fever
and the two patients who had abdominal pains and pruritus were
PMMoV RNA-positive.
Infection of host plants with PMMoV RNA-positive food
products
All N. tabacum cultivar Xanthi NN plants inoculated with each of
the three PMMoV RNA-positive food products developed local
Figure 1. Electron microscopy of Pepper mild mottle virus (PMMoV)-RNA positive samples. Footnote: The samples analyzed by electron
microscopy were (a) Tabasco sauce; (b) PMMoV purified from Tabasco sauce. The samples analyzed following immunogold staining were: (c) PMMoV
purified from Tabasco sauce; (d) a PMMoV-RNA positive patient’s stool sample; (e) PMMoV purified from Tabasco sauce stained with antibodies from
a non immunized mouse (negative control no.1) and (f) a rotavirus-positive sample (negative control no.2).
doi:10.1371/journal.pone.0010041.g001
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inoculation (Figures 2a–h). These lesions were observed on the
three inoculated leaves for each plant, whereas control plants
remained devoid of symptoms during an observation period of two
weeks post-inoculation. PMMoV RNA was detected using RT-
PCR from local lesions, PMMoV-like viral particles were observed
by electron microscopy, and systemic mosaic symptoms typical of
PMMoV were observed within 2–3 weeks post-inoculation on C.
annuum cultivar Yolo Wonder or N. benthamiana.
PMMoV RNA sequencing and phylogenetic analysis
PMMoV sequences corresponding to the 59 region of the
PMMoV genome were obtained from four Tabasco sauce samples
and thirteen patients, whereas sequences corresponding to a
fragment of the capsid protein gene were obtained from eleven
food products, including three Tabasco sauce samples, and
eighteen patients (Figures 3a and 3b, respectively; GenBank
accession numbers GQ427021–GQ427066). The BLAST analysis
of the nucleotide sequences from the 59 region produced only ten
relevant hits, after which the sequences no longer corresponded to
PMMoV (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The sequences
recovered from Tabasco sauce tended to cluster separately from
those recovered from patients (Figure 3a). The mean nucleotide
identity was 96.562.2% (range, 90.9–100%) for all PMMoV
sequences, 96.462.4% (91.0–100%) for sequences recovered in
the present study, 97.861.9% (93.9–100%) for sequences obtained
from GenBank and 67.161.0% (64.1–68.6) with a Tobacco mosaic
virus sequence. For the sequences of the capsid protein gene, the
mean nucleotide identity was 97.161.8% (90.8–100%) for all
PMMoV sequences, 97.261.9% (91.3–100%) for sequences
recovered in the present study, 97.562.4% (90.8–100%) for
sequences obtained from GenBank and 76.260.9% (73.4–77.7%)
with Tropical soda apple mosaic virus sequence. One cluster (cluster II-
1) contained four sequences from the present study (Figure 3b),
and 100% nucleotide identity was observed between the sequences
from two patients that received care in a Dermatology Unit and
from a spicy powder.
Anti-PMMoV Total Ig and IgM ELISA
The level of serum anti-PMMoV total and IgM antibodies was
examined by ELISA in a subset of 29 adult patients, 13 of which
had PMMoV-positive stool, as detected by PCR (Figures 4a and
4b). For the analysis of the IgM anti-PMMoV level, the optical
density (OD) for the substrate and antibody controls was 0.079
and 0.099, respectively. The mean OD was significantly higher in
patients with PMMoV RNA than in the controls (0.472 versus
0.325, p=0.013 (ANOVA); Figure 4b). Using the receiver
operating characteristic (ROC) curve test with a sensitivity of
100% and a specificity of 62%, a value of 0.320 was considered
positive for the detection of PMMoV-specific IgM (AUC=0.808;
95% confidence interval: 0.645–0.971; p=0.005). The proportion
of serum samples with an OD greater than 0.320 was significantly
higher for patients with PMMoV RNA-positive stool than for the
controls (p=0.0004). With this threshold, all 13 serum from
patients with PCR PMMoV-positive stool were seropositive,
whereas 10/16 (63%) sera from patients with PCR PMMoV-
negative stool were seronegative. Thus, the positive and negative
predictive values for having PCR-positive stool were 68% and
100%, respectively. For the analysis of the total anti-PMMoV
level, the optical density (OD) for the substrate and antibody
Table 2. Characteristics of individuals positive and negative for real-time PCR PMMoV RNA detection in stools.
PMMoV RNA real-time PCR
p-values (Odds ratio (95%
confidence limits for Odds ratio))
Positive Negative All
Children (,18 years of age)
Nb of individuals 1 136 137 -
Nb of stools samples 1 207 208 -
Gender (sex ratio M:F) 1:0 1.08 1.09 -
Age (years; mean +/2 SD (range)) 5 2.9+/24.1 (0–17.2) 2.9+/24.1 (0–17.2) -
Adults (.18 years of age)
Nb of individuals (nb (%)) 22 (7.2%) 282 (92.8%) 304 -
Nb of stools samples (nb (%)) 23 (6.4%) 334 (93.6%) 357 -
Gender (sex ratio M:F) 1.44 1.22 0.71
Age (years; mean +/2 SD (range)) 59.7+/219.4 (19–85) 59.9+/220.0 (18–96) NS
Nb of patients with sequential
stools samples (nb (%))
5 (22.7%
a) 30 (10.6%
b) 35 0.087 (2.47 (0.74–7.83))
Clinical units:
Dermatology units (nb (%)) 7 (35.0%) 13 (65.0%) 20 0.0000007 (9.66 (2.97–31.17))
c
Nephrology units (nb (%)) 4 (12.5%) 28 (87.5%) 32 0.074
d
Internal Medicine units (nb (%)) 3 (10.3%) 26 (89.7%) 29 0.12
e
Other clinical units (nb (%)) 8 (3.6%) 215 (96.4%) 223 -
Footnote: -, not tested; NS, not significantly statistically different; Nb, number. SD, standard deviation.
a% of individuals with PMMoV RNA-positive stools.
b% of individuals with PMMoV RNA-negative stools.
cVersus all other clinical units.
dVersus other clinical units than dermatology units.
eVersus other clinical units than dermatology units and nephrology units.
doi:10.1371/journal.pone.0010041.t002
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PMMoV RNA from stools.
PMMoV RNA real-time PCR (Nb of patients (%))
P-values (Odds ratio (95%
confidence limits for Odds ratio))
Positive (n=18) Negative (n=31) All (n=49)
Age.63 years
a 9 (50) 17 (55) 26 (53) 0.458
Male gender 12 (67) 18 (58) 30 (61) 0.286
Stools sample collected in:
Dermatology units 7 (39) 9 (29) 16 (33) 0.249
Nephrology units 4 (22) 8 (26) 12 (25) 0.532
Infectious diseases units 2 (11) 4 (13) 6 (12) 0.616
Internal medicine units 1 (6) 2 (7) 3 (6) 0.698
Endocrinology units 1 (6) 2 (7) 3 (6) 0.698
Hepato-gastro-enterology units 1 (6) 2 (7) 3 (6) 0.698
Cardiology units 1 (6) 2 (7) 3 (6) 0.698
Neurological surgery units 1 (6) 2 (7) 3 (6) 0.698
Any among the following source of
immune suppression
7 (39) 10 (32) 17 (35) 0.325
HIV infection/AIDS 0 (0) 1 (3) 1 (2) 0.633
Solid organ transplantation 2 (11) 2 (7) 4 (8) 0.470
Kidney transplantation 2 (11) 1 (3) 3 (6) 0.302
Hematopoietic stem cell transplantation 0 (0) 1 (3) 1 (2) 0.633
Any immunosuppressive therapy 6 (33) 9 (29) 15 (31) 0.379
Corticotherapy 4 (22) 6 (19) 10 (20) 0.542
Clinical signs:
Any among the following clinical signs 13 (72) 17 (55) 30 (61) 0.124
Nausea and/or vomiting 1 (6) 1 (3) 2 (4) 0.605
Diarrheoae 5 (28) 10 (32) 15 (31) 0.381
Abdominal pains 7 (39) 2 (7) 9 (18) 0.0079 (2.83 (1.53–5.22))
Oesophagitis 2 (11) 2 (7) 4 (8) 0.470
Gastritis 0 (0) 1 (3) 1 (2) 0.633
Gastric or duodenal ulcer 1 (6) 1 (3) 2 (4) 0.605
Colitis 0 (0) 2 (7) 2 (4) 0.395
Proctitis 1 (6) 0 (0) 1 (2) 0.367
Polyp 1 (6) 0 (0) 1 (2) 0.367
Prostatitis 1 (6) 1 (3) 2 (4) 0.605
Constipation 1 (6) 0 (0) 1 (2) 0.367
Any among the two following symptoms 3 (17) 0 (0) 3 (6) 0.044 (3.07 (2.02–4.65))
Diverticulosis 1 (6) 0 (0) 1 (2) 0.367
Diverticulitis 2 (11) 0 (0) 2 (4) 0.130 (2.94 (1.97–4.37))
Blood in stools 1 (6) 1 (3) 2 (4) 0.605
PMMoV RNA real-time PCR (Nb of patients (%))
P-values (Odds ratio (95%
confidence limits for Odds ratio))
Positive (n=18) Negative (n=31) All (n=49)
Clinical signs (continuation):
Any among the following clinical signs 9 (50) 8 (26) 17 (35) 0.051 (1.88 (0.92–3.84))
Pruritus 5 (28) 3 (10) 8 (16) 0.107 (1.97 (0.98–3.97))
Urticaria 1 (6) 0 (0) 1(2) 0.367
Eczema 2 (11) 1 (3) 3 (6) 0.302
Skin rash 0 (0) 2 (7) 2 (4) 0.395
Bullous skin rash 0 (0) 1 (3) 1 (2) 0.633
Dermatosis 0 (0) 1 (3) 1 (2) 0.633
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P-values (Odds ratio (95%
confidence limits for Odds ratio))
Positive (n=18) Negative (n=31) All (n=49)
Dermo-hypodermiitis 1 (6) 0 (0) 2 (4) 0.367
Erysipeloid rash 1 (6) 1 (3) 2 (4) 0.605
Erythrodermia 0 (0) 0 (0) 0 (0) -
Psoriasis 0 (0) 1 (3) 1 (2) 0.633
Purpura 1 (6) 1 (3) 2 (4) 0.605
Furonculosis 1 (6) 0 (0) 1 (2) 0.367
Impetigo 1 (6) 0 (0) 1 (2) 0.367
Vitiligo 0 (0) 1 (3) 1 (2) 0.633
Hepatomegaly 2 (11) 2 (7) 4 (8) 0.470
Cirrhosis 1 (6) 2 (7) 3 (6) 0.698
Fever 7 (39) 4 (13) 11(22) 0.042 (2.20 (1.13–4.30))
Other clinical signs:
Anorexia 0 (0) 3 (9) 3 (6) 0.244
Asthenia 3 (17) 6 (19) 9 (18) 0.567
Renal insufficiency 3 (17) 14 (45) 17 (35) 0.025 (0.38 (0.13–1.12))
Dialysed renal insufficiency 3 (17) 4 (13) 7 (14) 0.512
Diabetes mellitus 5 (28) 5 (16) 10 (20) 0.268
Vascularitis 0 (0) 0 (0) 0 (0) -
Increased blood pressure 9 (50) 14 (45) 23 (46) 0.377
Joint pains 2 (11) 0 (0) 2 (4) 0.130 (2.94 (1.97–4.37))
Asthma 1 (6) 1 (3) 2 (4) 0.605
Allergy 2 (11) 1 (3) 3 (6) 0.302
Thrombosis history 2 (11) 2 (7) 4 (8) 0.470
Pneumonia 5 (28) 3 (10) 8 (16) 0.107 (1.97 (0.98–3.97))
Lung clinical symptoms 5 (28) 5 (16) 10 (20) 0.268
PMMoV RNA real-time PCR (Nb of patients (%))
P-values (Odds ratio (95%
confidence limits for Odds ratio))
Positive Negative All
Biological signs:
Increased levels of blood markers of inflammation
b 9 (64) 17 (61) 26 (62) 0.419
Leukocyte count .10.000/mm
3 2 (11) 9 (31) 11 (23) 0.111
Lymphopenia 9 (56) 12 (44) 23 (50) 0.238
Polynuclear neutrophil count .10,000/mm
3 3 (18) 8 (28) 11 (24) 0.349
Polynuclear eosinophil count .500/mm
3 2 (11) 2 (7) 4 (8) 0.484
Increased levels of IgE antibodies 2 (11) 4 (13) 6 (12) 0.616
Antinuclear antibodies positivity 1 (6) 0 (0) 1 (2) 0.367
Increased levels of liver enzymes 6 (33) 9 (30) 15 (31) 0.406
ALT .45 IU/L 0 (0) 4 (24) 4 (16) 0.188
Gammaglutamyltransferase .45 IU/L 3 (38) 5 (29) 8 (32) 0.513
Bilirubinemia .35 mmol/L 1 (13) 0 (0) 1 (5) 0.381
Positive electron microscopy 17 (94) 0 (0) 17 (53) ,10
26 (15.00 (2.26–99.64))
Total anti-PMMoV antibodies positivity in serum 6 (75) 2 (29) 8 (53) 0.100 (2.63 (0.76–9.05))
IgM Anti-PMMoV antibodies positivity in serum 8 (100) 3 (43) 11 (73) 0.026 (nc)
Footnote: -. undefined; Nb, Number; Nc, not calculable; p values ,0.05 are in boldface.
a63 years was the median age of the adult patients tested in the case-control study.
bBlood markers of inflammation were elevated erythrocyte sedimentation rate, and/or C-reactive protein and fibrinogen levels in serum.
doi:10.1371/journal.pone.0010041.t003
Table 3. Cont.
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significantly higher in patients with PMMoV RNA than in the
controls (0.663 versus 0.444, p=0.028; Figure 4a). A cut-off value
of 0.565 (estimated using the ROC curve test with a sensitivity of
69% and a specificity of 81%) was used (AUC=0.724; 95%
confidence interval: 0.529–0.918; p=0.041). The proportion of
serum samples for which the optical density (OD) was greater than
0.565 was significantly higher for patients with PMMoV-positive
stool than for those with PMMoV-negative stool (p=0.0070).
Using this threshold, 9 (69%) of the 13 sera from patients with
PCR PMMoV-positive stool were seropositive, whereas 13 (82%)
of the 16 sera from patients with PCR PMMoV-negative stool
were seronegative. Additionally, serological patterns indicating
past infection (i.e., a positive total antibody result, but a negative
IgM result) and negative total antibody and IgM testing were
observed in two and eight PMMoV-negative patients, respectively,
but in none of the PMMoV-positive patients (p=0.0004). Finally,
in the case-control study (Table 3), positive testing for anti-
PMMoV IgM antibody was significantly more frequent in case-
patients than in control-patients.
Discussion
We detected PMMoV RNA by real-time PCR in stool from 22 of
304 (7.2%) adult patients and 1 of 208 children who received care in
public hospitals. The present study therefore confirms the recent
finding by Zhang et al. who identified PMMoV as the major RNA
virus in human stool in a metagenomic study [7]. However, we
found a much lower prevalence of PMMoV RNA-positive stool by
r e a l - t i m eP C Ra m o n ga d u l tp a t i e n t st h a nZ h a n get al.,w h od e t e c t e d
the viral genome in 12 of 18 fecal samples (66.7%) using RT-PCR.
This difference might be explained either by a lower sensitivity for
real-time PCR or the lower exposure to PMMoV in our patients.
We recovered PMMoV RNA sequences from 57% of food products
containing pepper or spice and purchased from grocery stores in
Marseille (southeastern France), indicating that these products
represent a common source of viruses through ingestion. In
addition, in food products and patient’s stool, we could visualize
by electron microscopy complete viruses whose shape and size are
consistent with PMMoV and that reacted with PMMoV-specific
antibodies in the immunogold staining experiments. Moreover, 46
new PMMoV sequences corresponding to two regions of the viral
genome were recovered from food products or patients’ stool. Four
phylogenetic clusters were identified, and one of them (II-1) included
sequences from both patients and a putative food source.
Furthermore, three PMMoV RNA-positive food products were
found to contain virus particles infectious to host plants.
We also identified statistically significant differences in the
occurrence of fever, abdominal pains, and pruritus and the
detection of specific immune responses to PMMoV in the case-
control study. We, therefore, believe that we provide the first
evidence that plant viruses may cause disease in humans. Fever
and abdominal pains, which were significantly more common in
PMMoV-positive patients (39% for both clinical features) than in
Figure 2. Local lesions typical of PMMoV infection on Nicotiana tabacum cultivar Xanthi NN plants following inoculation of
processed PMMoV RNA-positive food products. Footnote: Leaves of Nicotiana tabacum cultivar Xanthi NN plants (a, e) non inoculated
(negative control); (b, f) inoculated with buffer only (negative control); (c, and detail: d) inoculated with a processed PMMoV RNA-positive Tabasco
sample; (g, and detail: h) inoculated with a PMMoV RNA-positive food product (no. 17; Table 1).
doi:10.1371/journal.pone.0010041.g002
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were also present in the only PMMoV RNA-positive child. These
symptoms might not be caused by PMMoV but by consumption of
spicy food. Otherwise, they may be fortuitously related to an
associated unknown infectious agent or to an allergic or toxic
cofactor. Nevertheless, the presence of a specific immune response
to PMMoV reinforces the hypothesis that this plant virus was the
cause of the symptoms in these patients. Indeed, anti-PMMoV
IgM antibodies were detected in all PMMoV-positive patients,
significantly more frequently than in the controls. The concurrent
detection of PMMoV RNA and antibodies to PMMoV indicates
that this virus is not a neutral component of the human gut flora.
On the contrary, our findings suggest that PMMoV may infect
humans and cause clinical symptoms. We believe that these
preliminary data may prompt further studies on the pathogenic
role of PMMoV in humans. Finally, the higher prevalence of
PMMoV RNA among patients who received care in Dermatology
Units deserves further attention, as it was high (35%).
To date, plant viruses and vertebrate viruses are believed to
exist in two distinct and non overlapping biological niches, and
they are not known to share common hosts in the plant or animal
kingdoms [14–15]. Therefore, to date, plant viruses have not been
described as pathogens for vertebrates or humans or known even
to infect them [16]. This paradigm is underscored by the growing
body of data about the use of plant virus–based vaccines, which
are considered as safe tools that might be useful in treating chronic
viral infections and cancer in the future [17–20]. However, the
boundaries between plants and animals might not be so hermetical
for plant viruses, and, to our knowledge, no experimental model
has been described that would allow us to rule out a pathogenic
role for plant viruses in vertebrates. The recent work of Zhang et
al. challenged this dogma, as it was neutral, technology-driven
research that was not trying to confirm a former hypothesis [7,21].
That work identified plant viruses as the most common viral
inhabitants of the human gut flora, PMMoV being the most
prevalent. In addition, a recent study demonstrated that PMMoV
Figure 3. Phylogenetic comparison of PMMoV nucleotide sequences recovered in the present study and corresponding (a) to a
region located near the 59 end of the genome or (b) to a region in the capsid gene to PMMoV sequences selected from GenBank.
Footnote: The phylogenetic trees were constructed using the neighbor-joining method based on the 59 region (a) of the PMMoV genome or a region
in the capsid gene (b). The PMMoV sequences recovered from patients’ stool in the present study are in the boldface, white font and are indicated by
a black square. Their name is labeled as follows: Mars_Laboratory identification number_Gender-Age_Clinical unit where the patient received care.
The PMMoV sequences recovered from food products in the present study are in a boldface and are indicated by a gray square. Their name is labeled
as follows: Mars_Name of the food product_Country where food product was manufactured. The remaining PMMoV sequences were obtained from
GenBank. Their name is labeled as follows: GenBank Accession no._Coutry of origin_Year of submission to GenBank. Bootstrap values are indicated
when greater than 50% as a percentage obtained from 1,000 resamplings of the data. The scale bar indicates the number of nucleotide substitutions
per site. The sequence of Tobacco mild green mosaic virus (GenBank Accession No. NC_001556) and Tropical soda apple mosaic virus (GenBank
Accession No. AY956381) were used as outgroups.
doi:10.1371/journal.pone.0010041.g003
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positive and PMMoV RNA-negative stool. The dashed lines indicate the optical density cut-off values that were chosen for positive PMMoV
serology using the receiver operating characteristic (ROC) curve test.
doi:10.1371/journal.pone.0010041.g004
Table 4. Summary of postulates and findings about interactions of PMMoV with the host immune system, its replication in non-
plant tissues, and its potential link with clinical signs.
Postulate Plant virus Finding Reference
PMMoV may interact with the host
immune system
Pepper mild mottle virus Specific immune response as indicated by positive anti-
PMMoV IgM antibody testing in patients with PMMoV in stool
Present study
Cowpea severe mosaic virus,
Alfalfa mosaic virus
Evidence of systemic immune response (specific synthesis of
IgG and IgA in sera) in mice immunized orally with Cowpea
severe mosaic virus (CPSMV) in the absence of immunoadjuvants.
Similar results were observed with viral particles of Alfalfa
mosaic virus and chimeric plant virus particles
[23–25]
Tomato spotted wilt virus Induction of a strong immune response in Frankliniella
occidentalis, its main insect vector
[26]
Pepper mild mottle virus High PMMoV loads in stool of patients and food products
containing pepper
[7], Present study
PMMoV may replicate in humans Pepper mild mottle virus High PMMoV loads in stool of patients and food products
containing pepper
[7], Present study
Pepper mild mottle virus,
Tobamovirus
High viral stability [8,34,35]
Pepper mild mottle virus PMMoV detected from human stool is viable [7]
Tomato spotted wilt virus;
Maize rayado fino virus
Some plant viruses are able to multiply
in non-plant tissue (in insect tissues)
[26–28]
Nanovirus Evidence that a plant virus switched hosts to infect a vertebrate [16]
Tomato spotted wilt virus Expression of a viral polymerase-bound factor turned human
cell lines, HeLa and diploid fibroblasts, permissive to Tomato
spotted wilt virus
[30]
Tobacco mosaic virus Plant virus particles could be assembled in Escherichia coli [36]
PMMoV may induce clinical signs Tomato yellow leaf curl virus Reduction of lifespan and fecundity of the insect vector
(Bemisia tabaci) during viral infection
[29]
Tobacco mosaic virus Recovery of culturable tobacco mosaic virus from sputum
and thoracentesis fluids obtained from cigarette smokers
with a history of pulmonary disease
[31–33]
Pepper mild mottle virus Fever and abdominal pains are significantly more frequent in
patients with PMMoV-positive stool
Present study
doi:10.1371/journal.pone.0010041.t004
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(USA), at concentrations ranging between 8.0610
5 and 2.2610
7
copies/ml [22]. Beyond these findings, our results, together with
previous data, suggest that the relationship between plant viruses
and animals may deserve further re-evaluation using modern
microbiologic tools (Table 4). The oral administration of Cowpea
severe mosaic virus, another plant virus, has been previously shown to
induce a durable and systemic immune response in mice without
requiring the co-administration of an adjuvant [23], and similar
results have been observed in mice using Alfalfa mosaic virus and
chimeric plant virus particles [24–25]. In addition, some plant
viruses can replicate in insect tissues, as illustrated by Tomato spotted
wilt virus and Maize rayado fino virus [26–28]. Furthermore, a
reduction in the lifespan and fecundity of insects (Bemisia tabaci)
during infection with Tomato yellow leaf curl virus has been previously
observed, indicating that this plant virus had some features of an
insect pathogen [29]. It has been also suggested, based on viral
sequence analysis, that during evolution, plant-infecting viruses
(previously known as plant circoviruses and recently reclassified in
the genus Nanovirus) switched hosts to infect a vertebrate and then
recombined with a vertebrate-infecting virus [16]. Moreover, it
has been shown recently that Tomato spotted wilt virus could replicate
in two human cell lines, HeLa and diploid fibroblasts [30]. This
virus is one of the most important plant pathogens worlwide, and it
causes mild infection on its main insect vector, Frankliniella
occidentalis, in which it induces a strong immune response [26].
Finally, the possible involvement of plant viruses in human
diseases was questioned several decades ago. Indeed, culturable
Tobacco mosaic virus could be recovered from sputum and
thoracentesis fluids obtained from cigarette smokers with a history
of pulmonary disease, including lung cancer [31–33]. Taken
together, these experimental data, coupled with the previous
results reported by Zhang et al. and our findings, favor the
hypothesis of a pathogenic role for PMMoV. It should be
highlighted that PMMoV, like other tobamoviruses, are known to
be extraordinarily resistant to heat and desiccation [34–35].
Moreover, although this deserves to be investigated in further
studies, the viability and infectivity to host plants were evidenced
for PMMoV recovered from food products in the present study
and from stools in Zhang et al.’s study [7]. Additionally, we
visualized complete viral particles in stool by electron microscopy.
In summary, we confirmed that humans may carry a high
PMMoV load, likely acquired from food products, and we
documented that PMMoV might not only be a common
inhabitant of the human gut but may also interact with the
human immune system and cause clinical symptoms. These results
should prompt further studies to re-evaluate whether or not plant
viruses, including PMMoV, may have a pathogenic role in
humans.
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